Stockreport

Protalix BioTherapeutics Inc (PLX) Q3 2024 Earnings Call Highlights: Revenue Surge and ... [Yahoo! Finance]

Protalix BioTherapeutics, Inc. (DE)  (PLX) 
PDF Cost of Goods Sold: $8.4 million, a 71% increase from $4.9 million in Q3 2023. Research and Development Expenses: $3 million, a 19% decrease from $3.7 million in Q3 2 [Read more]